Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.
about
Cancer-associated thrombotic microangiopathyA new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injuryHematopoietic cell transplantation-associated thrombotic microangiopathy: a review of pathophysiology, diagnosis, and treatmentTransplant-associated thrombotic microangiopathy: opening Pandora's box.Venous thromboembolism following hematopoietic stem cell transplantation-a systematic review and meta-analysis.Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting?Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis.A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.Transplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus.Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxisRisk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease.Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy.Eculizumab in Transplant-Associated Thrombotic Microangiopathy.Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults.A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL).Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.Remission of microangiopathy in transplanted thalassemic child.Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation.Thrombotic microangiopathy in haematopoietic cell transplantation: an update.Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantationReduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomasExtended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysisReduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxisCosts of allogeneic hematopoietic cell transplantation with high-dose regimens.The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies.Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island.Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.Quality of life associated with sirolimus for prevention of graft-versus-host disease: results from a randomized trial.The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis.Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GVHD prophylaxis.The efficacy and safety of sirolimus-based graft-versus-host disease prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials.Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy?Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation
P2860
Q26738984-D5930A0D-E567-4530-B6BE-524902610017Q26992169-63E54129-E1BD-44C8-B34C-F293891C9833Q28069228-625414A5-EF67-42A8-B477-5DB6AFA1D749Q30235311-7849825D-8656-4F62-9BC7-27A7CC9E3FD1Q30251535-E0740491-B8D4-4C64-B816-EFCDBB937936Q33375739-15361F94-B784-4380-94E3-7186DAFA03F2Q33382787-54690154-D1B9-4D4F-83EA-BA5D8CC78311Q33387336-2C3346F9-66F7-423E-9DF9-0A77B763A2A4Q33395253-9176653C-FA2D-4A11-AC57-7E12C27555D7Q33403897-8346B429-B710-40AD-BB70-11B7D1FA9E1EQ33413498-47AB347C-EB2C-46A8-A4DD-66FE308753F5Q33424311-B0B3F465-C442-4309-9B9C-5F24D2A606FCQ33424902-FB505424-08BE-4EF7-A0AC-68B238575A4BQ33425079-906D88E7-6CBA-4560-8F90-CE303B9A244FQ33847973-AFDE056D-58A0-4A30-B73C-3762CFC859A1Q33924570-515017F6-B5AF-449D-86CC-BD5EB57C14A9Q34077792-4E648530-EFCD-4594-9B15-3FA6668E26D6Q34207695-46914D9F-CAE6-40FA-AF16-D0EA5C29A9D4Q34272554-74ECDF31-B663-4C18-8D2E-5B40BA03B719Q34316381-6D9FE0EA-92F4-4108-B141-74ADF1ABCF4FQ34451427-6A298ECF-8001-4FF7-8A45-9D9364E17D3DQ34510280-DC322660-562A-4EB5-BF38-4E320FEF205EQ35098992-743A2948-ED5C-418A-AD76-6E87B78514BAQ35184589-867A1496-5706-425A-98D0-29656E456CFEQ35683306-8B84E95B-A953-4C3E-B9CA-378C8B24661CQ35750957-345DA7F4-0BBD-4EF8-B204-EC62ED7B5530Q35900978-CBED8843-E635-4AFA-A0B5-850647D74607Q36206849-1B549DAA-CA2A-4D25-9625-AA188B1060B7Q36485256-3AE56219-D7CF-47EF-AC16-EE15ADE96198Q36862464-9AA8F405-D903-4778-9C14-15F58FA1A85EQ36997723-41792A1F-DCAF-49A5-8D78-F5F084032BBAQ37000488-E4350638-7DCB-4BE3-B0A2-E62B61D01B64Q37001941-77CBB1EF-6B26-46F5-AF45-C4DDC2E47095Q37618931-0943BFFD-9571-4ADA-AE81-18205823543AQ37670062-A2FD5749-2C6E-4826-98EF-CBCFF0A98DADQ38010596-A1FE08A6-4288-4090-9117-87C89172AB28Q38202155-648AE970-11CB-4208-80EB-2F9D83797FB3Q38413246-2AE37749-7CE5-4FDF-B1CB-28227F6DA974Q38806679-B09D7084-CF32-44D3-AF14-22539549BC94Q40577820-6C1ED2DB-2DEF-457F-A2F7-828DE2C50C38
P2860
Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Sirolimus and thrombotic micro ...... tic stem cell transplantation.
@ast
Sirolimus and thrombotic micro ...... tic stem cell transplantation.
@en
type
label
Sirolimus and thrombotic micro ...... tic stem cell transplantation.
@ast
Sirolimus and thrombotic micro ...... tic stem cell transplantation.
@en
prefLabel
Sirolimus and thrombotic micro ...... tic stem cell transplantation.
@ast
Sirolimus and thrombotic micro ...... tic stem cell transplantation.
@en
P2093
P1476
Sirolimus and thrombotic micro ...... tic stem cell transplantation.
@en
P2093
Colm Magee
Corey Cutler
Edwin Alyea
Haesook T Kim
Joseph H Antin
N Lynn Henry
Robert Soiffer
Vincent Ho
P304
P356
10.1016/J.BBMT.2005.04.007
P577
2005-07-01T00:00:00Z